UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000024529 |
|---|---|
| Receipt number | R000028223 |
| Scientific Title | The Development of Psychometric Property of Japanese version of Scale of Attitudes Toward Pharmacist-Physician Collaboration |
| Date of disclosure of the study information | 2016/10/24 |
| Last modified on | 2021/03/28 18:26:18 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The Development of Psychometric Property of Japanese version of Scale of Attitudes Toward Pharmacist-Physician Collaboration
Acronym
The Development of Psychometric Property of Japanese version of Scale of Attitudes Toward Pharmacist-Physician Collaboration
Scientific Title
The Development of Psychometric Property of Japanese version of Scale of Attitudes Toward Pharmacist-Physician Collaboration
Scientific Title:Acronym
The Development of Psychometric Property of Japanese version of Scale of Attitudes Toward Pharmacist-Physician Collaboration
Region
| Japan |
Condition
Condition
students
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this study is to develop the Japanese version of scale of attitudes toward pharmacist-physician collaboration (SATP2C) and to assess the reliability and validity of SATP2C.
Basic objectives2
Others
Basic objectives -Others
The ability to detect change is assessed by comparing SATP2C score before and after school joint curriculum intended for the medical students and pharmacy students.
Trial characteristics_1
Others
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
The Psychometric Property of Japanese version of SATP2C
Key secondary outcomes
Changes in the score of SATP2C through interprofessional education
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Physician, pharmacist, medical student, or pharmacy student
2. Native Japanese speaker
Key exclusion criteria
None
Target sample size
120
Research contact person
Name of lead principal investigator
| 1st name | Kanayuki |
| Middle name | |
| Last name | Kitahara |
Organization
Showa University
Division name
School of pharmacy
Zip code
1428666
Address
Hatanodai 1-5-8, Shinagawa-ku, Tokyo
TEL
03-3784-8467
k.kitahara@cmed.showa-u.ac.jp
Public contact
Name of contact person
| 1st name | Kanayuki |
| Middle name | |
| Last name | Kitahara |
Organization
Showa University
Division name
School of pharmacy
Zip code
1428666
Address
Hatanodai 1-5-8, Shinagawa-ku, Tokyo
TEL
03-3784-8467
Homepage URL
k.kitahara@cmed.showa-u.ac.jp
Sponsor or person
Institute
Showa university
Institute
Department
Personal name
Funding Source
Organization
Self funding
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Tokyo University of Pharmacy and Life Sciences, Department of Practical Pharmacy
Tohoku University School of Medicine
Name of secondary funder(s)
IRB Contact (For public release)
Organization
School of Medicine, Showa University ETHICAL COMMITTEE
Address
1-5-8, Hatanodai, Shinagawa-ku, Tokyo
Tel
03-3784-8022
gakuji@ofc.showa-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 10 | Month | 24 | Day |
Related information
URL releasing protocol
https://www.tandfonline.com/doi/abs/10.1080/13561820.2020.1834369?journalCode=ijic20
Publication of results
Published
Result
URL related to results and publications
https://www.tandfonline.com/doi/abs/10.1080/13561820.2020.1834369?journalCode=ijic20
Number of participants that the trial has enrolled
137
Results
The scale showed confirmed reliability; Cronbach's alphas were 0.79 for Responsibility and Accountability, 0.68 for Shared Authority, and 0.67 for Interdisciplinary Education. Pre and post-IPE, each mean subscale score increased: Responsibility and Accountability, 0.7+/-0.4, Shared Authority, 0.2+/- 0.3; and Interdisciplinary Education, 0.3+/-0.2. Although the total score increased (1.2+/-0.7), this was non-significant.
Results date posted
| 2021 | Year | 03 | Month | 28 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
| 2020 | Year | 11 | Month | 15 | Day |
Baseline Characteristics
The participants in Cohort 1 were 21 physicians and 62 pharmacists. The participants in Cohort 2 were 25 medical students and 29 pharmacy students.
Participant flow
The IPE program in this research was a five-day program in which students in the fifth grade of pharmacy school, dental school, and medical school, and fourth grade nursing students cooperated with each other to care for one patient in each ward in eight Showa University-branched hospitals. For students who had not experienced IPE, conducting only one day of IPE may change their attitude toward other professions; therefore, it is difficult to implement test and retest reliability to verify replicability. Consequently, in this study, two cohorts were established. Cohort 1 evaluated replicability, and Cohort 2 assessed criterion-related validity and responsiveness. In Cohort 1, replicability was assessed for physicians and pharmacists using test-retest reliability. Physicians and pharmacists completed background survey items and the SATP2C on the first day and then completed the SATP2C again on the second day. In Cohort 2, we evaluated responsiveness, internal consistency, and validity among medical and pharmacy students, who answered the SATP2C and RIPLS on the first day. After the end of IPE, the medical and pharmacy students answered the SATP2C, RIPLS, and global impression scale again.
Adverse events
none
Outcome measures
pre-and post IPE SATP2C score, post IPE Global impression
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2016 | Year | 08 | Month | 22 | Day |
Date of IRB
| 2016 | Year | 09 | Month | 30 | Day |
Anticipated trial start date
| 2016 | Year | 10 | Month | 24 | Day |
Last follow-up date
| 2017 | Year | 02 | Month | 28 | Day |
Date of closure to data entry
| 2017 | Year | 03 | Month | 01 | Day |
Date trial data considered complete
| 2017 | Year | 03 | Month | 01 | Day |
Date analysis concluded
| 2018 | Year | 06 | Month | 30 | Day |
Other
Other related information
Reliability of SATP2C is assessed in the cohort of physicians and pharmacists by measuring two pointson the first day and the second day. Response is assessed by comparing SATP2C score before and after multi-school joint curriculum in Showa university intended for medical students and pharmacy students. Criterion-related validity is evaluated by applying RIPLS.
Management information
Registered date
| 2016 | Year | 10 | Month | 23 | Day |
Last modified on
| 2021 | Year | 03 | Month | 28 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028223
